Strides Pharma Science Ltd Sees Bullish Momentum Shift Amid Strong Technical Signals

Technical Trend Evolution and Price Momentum

Recent technical assessments reveal that Strides Pharma’s price momentum has strengthened significantly. The stock closed at ₹1,184.05 on 9 Sep 2026, marking a modest day gain of 0.48% from the previous close of ₹1,178.40. Intraday trading saw a high of ₹1,205.00 and a low of ₹1,155.70, indicating healthy volatility within a bullish range. The 52-week high stands at ₹1,231.45, while the 52-week low is ₹769.60, highlighting substantial appreciation over the past year.

The technical trend has upgraded from mildly bullish to bullish, reflecting improved investor sentiment and stronger price action. This shift is corroborated by daily moving averages, which currently signal a bullish stance, suggesting that short-term price momentum is aligned with longer-term upward trends.

MACD and RSI: Mixed but Improving Signals

The Moving Average Convergence Divergence (MACD) indicator presents a nuanced picture. On a weekly basis, the MACD remains mildly bearish, indicating some short-term consolidation or profit-taking phases. However, the monthly MACD has turned bullish, signalling that the longer-term momentum is gaining strength. This divergence between weekly and monthly MACD readings suggests that while short-term fluctuations may persist, the overarching trend favours upward movement.

Relative Strength Index (RSI) readings for both weekly and monthly periods currently show no definitive signal, hovering in neutral zones. This absence of overbought or oversold conditions implies that the stock has room to appreciate further without immediate risk of a technical correction, which is a positive sign for momentum traders.

Bollinger Bands and Moving Averages Confirm Uptrend

Bollinger Bands on both weekly and monthly charts are bullish, indicating that price volatility is expanding upwards and the stock is trending near the upper band. This pattern often precedes continued price appreciation as buying pressure intensifies. Complementing this, daily moving averages reinforce the bullish momentum, with the stock price consistently trading above key averages, signalling strong support levels and reduced downside risk.

Other Technical Indicators: KST, Dow Theory, and OBV

The Know Sure Thing (KST) oscillator remains mildly bearish on both weekly and monthly timeframes, suggesting some caution in momentum strength. Meanwhile, Dow Theory assessments are mildly bullish weekly but mildly bearish monthly, reflecting a transitional phase where short-term optimism contrasts with longer-term caution.

On a more encouraging note, the On-Balance Volume (OBV) indicator is bullish across weekly and monthly charts, signalling that volume trends support price gains. This volume-price confirmation is critical, as it indicates that institutional and retail investors are accumulating shares, reinforcing the sustainability of the uptrend.

Comparative Returns Highlight Strong Outperformance

Strides Pharma’s price momentum is further validated by its impressive returns relative to the Sensex benchmark. Over the past week, the stock surged 15.7%, while the Sensex declined by 1.78%. This outperformance extends across multiple time horizons: a 17.58% gain over one month versus a 3.72% Sensex decline; a year-to-date return of 31.22% compared to the Sensex’s negative 11.32%; and a one-year gain of 34.39% against the Sensex’s 6.45% loss.

Longer-term performance is even more striking. Over three years, Strides Pharma has delivered a staggering 438.03% return, dwarfing the Sensex’s 13.48%. Five-year and ten-year returns of 334.43% and 187.33% respectively also far exceed the Sensex’s 29.75% and 160.21% gains. This consistent outperformance underscores the stock’s strong growth trajectory and resilience within the Pharmaceuticals & Biotechnology sector.

Mojo Score Upgrade and Market Capitalisation Context

Reflecting these positive developments, MarketsMOJO has upgraded Strides Pharma’s Mojo Grade from Hold to Buy as of 8 Sep 2026, with a robust Mojo Score of 71.0. This upgrade signals increased confidence in the stock’s fundamentals and technical outlook. The company is classified as a small-cap, which often implies higher volatility but also greater growth potential, making it an attractive proposition for investors seeking exposure to the pharmaceutical innovation space.

Investment Implications and Outlook

For investors analysing Strides Pharma, the convergence of bullish technical indicators, strong volume support, and superior relative returns presents a compelling case for accumulation. The absence of RSI extremes suggests that the stock is not yet overextended, while the bullish monthly MACD and Bollinger Bands point to sustained upward momentum. However, the mildly bearish weekly MACD and KST indicators advise caution in the short term, recommending a measured approach to position sizing and entry timing.

Given the company’s sector positioning in Pharmaceuticals & Biotechnology, an industry often driven by innovation, regulatory approvals, and patent cycles, technical momentum shifts can provide timely signals ahead of fundamental catalysts. The current technical upgrade aligns well with Strides Pharma’s historical performance and recent market dynamics, suggesting that the stock is poised for further gains if broader market conditions remain supportive.

Conclusion: A Bullish Technical Reset in Progress

In summary, Strides Pharma Science Ltd is exhibiting a clear technical reset towards a bullish trajectory, supported by improved moving averages, bullish Bollinger Bands, and a positive monthly MACD. While some weekly indicators suggest short-term caution, the overall momentum and volume trends favour further appreciation. The stock’s strong relative returns compared to the Sensex reinforce its appeal as a growth-oriented small-cap within the Pharmaceuticals & Biotechnology sector.

Investors should monitor ongoing technical signals alongside fundamental developments to capitalise on this momentum shift. The recent upgrade to a Buy rating by MarketsMOJO further validates the stock’s potential, making it a noteworthy candidate for portfolios seeking exposure to innovative pharmaceutical companies with proven staying power and growth prospects.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →